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The endothelium maintains a vascular barrier by controlling platelet and immune cell
interactions, capillary tone and interendothelial cell (EC) adherence. Here we suggest
common elements in play during viral infection of the endothelium that alter normal EC
functions and contribute to lethal hemorrhagic or edematous diseases. In viral reservoir
hosts, infection of capillaries and lymphatic vessels may direct immunotolerance without
disease, but in the absence of these cognate interactions they direct the delayed onset
of human disease characterized by thrombocytopenia and vascular leakage in a severe
endothelial dysfunction syndrome. Here we present insight into EC controls of hemostasis,
immune response and capillary permeability that are altered by viral infection of the
endothelium.
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The role of the endothelium in maintaining fluid barrier func-
tions of capillaries is clear, obvious and fundamental to virally
induced hemorrhagic and edematous disease. Endothelial cells
(ECs) control vascular permeability through a dynamic set of
“fail-safe” systems. ECs permit fluid and cellular efflux without
leakage, yet respond to diverse signals from tissues and the cir-
culation, and elicit responses that regulate platelets, complement
and immune cell activation as well as capillary dilation and per-
meability (Luscher and Barton, 1997; Willoughby and Loscalzo,
2002; Orfanos et al., 2004; Aird, 2008; Dvorak, 2010). However,
it is often overlooked that EC receptors, signaling pathways and
activation responses are as distinct and varied as those of T and B
cells. In fact, EC signaling pathways are uniquely wired to avoid
apoptosis, T cell targeting and disruption of the endothelium.
The checks and balances built into averting lethal capillary leakage
suggest that several EC controls are bypassed by viruses that cause
hemorrhagic and edematous disease.
Except for the outcome, the mechanisms of vascular dysfunc-
tion in virally induced capillary leakage are poorly understood.
Viral infection of the endothelium is difficult to study and by
default roles for capillary leakage are consigned to more easily
assessed blood constituents. In viral infections the vasculature
is largely considered a conduit and secondary to the circulating
cytokines, suggested to form a “cytokine storm” that acts on the
endothelium. Yet, if cytokine responses were the cause of vascular
leakage, a wide variety of viruses, like influenza virus, should
be hemorrhagic (Teijaro et al., 2011). Similar patient cytokine
responses are observed during dengue fever (DF), that occurs
in the absence of hemorrhage or edema, and in patients that
develop dengue hemorrhagic fever (DHF) and dengue shock
syndrome (DSS; Halstead, 2002, 2008). In fact, while many viruses
cause a systemic cytokine storm there are only a few viruses
that cause hemorrhagic disease. Opinions are changing on the
role of the cytokine storm in virology, sepsis and autoimmune
diseases since the same cytokines are recorded without vascular
collapse or shock. An expanded, paradigm referred to as “severe
endothelial dysfunction syndrome” has been forwarded by focus
groups at the National Heart Lung and Blood Institute to more
accurately reflect viral and bacterial vascular leak syndromes
(http://www.nhlbi.nih.gov/research/reports/2010-bsrts.htm).
What differentiates viruses that cause hemorrhage, edema
and shock from others? Infection of the endothelium combined
with thrombocytopenia, capillary permeability and the control
of immune cells, directly or by tolerance, are high on a list of
EC regulated responses associated with virally induced vascular
leakage.
ENDOTHELIAL CELL REGULATED TOLERANCE AND VIRAL
HEMORRHAGE DISEASE
Viruses that rapidly infect and spread cause acute self-limited
infections that are in general cleared by immune responses with-
out causing thrombocytopenia or vascular leakage. Herpes viruses
and non-hemorrhagic arenaviruses (AVs) infect immune and
ECs without thrombocytopenia or capillary leakage and estab-
lish persistent viral infections, in humans or hosts, by direct-
ing immunotolerance (Adler and Sinzger, 2009; Kunz, 2009).
In contrast, AVs that cause hemorrhagic or edematous disease
(Sabia, Lassa, Mopeia, Junin, etc.) induce thrombocytopenia 1–2
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weeks post-infection and fail to tolerize humans, but persistently
and asymptomatically infect their small mammal hosts (Kunz,
2009; Charrel and de Lamballerie, 2010; Moraz and Kunz, 2011).
Ebola virus (EBOV) also infects human immune, dendritic and
ECs causing thrombocytopenia, lymphopenia and immune and
EC dysfunction 1–3 weeks after inoculation (Chen and Cosgriff,
2000; Schnittler and Feldmann, 2003; Aleksandrowicz et al.,
2008). Similar to other viral-host infections, EBOV presumably
establishes persistence in its infected reservoir hosts (possibly fruit
bats), without known disease, and it can be reasoned that EBOV
attempts tolerizing humans and subsequently causes immune,
platelet and EC dysfunction (Schnittler and Feldmann, 2003;
Mohamadzadeh et al., 2007). EBOV and AVs have in common
their ability to asymptomatically establish persistent infections of
hosts despite infecting immune and ECs. In humans both viruses
cause vascular leakage characterized by a long onset period prior
to hemorrhagic or edematous disease and are resistant to inter-
feron and replication inhibitors when patients are symptomatic.
These findings are consistent with failed attempts to establish
persistence in humans. Inactivation of the immune system may
also contribute to an extended period of EC infection that alters
the delicate balance of EC regulated hemostasis.
ROLE FOR PD-L1/PD-1 RESPONSES IN CAPILLARY
PERMEABILITY
Tolerance can be mediated by immune or EC responses and
many excellent reviews address T cell exhaustion and regulation
(Francisco et al., 2010; Jin et al., 2011; Kamphorst and Ahmed,
2013; Penaloza-MacMaster et al., 2014). In persistent AV [lym-
phocytic choriomeningitis virus (LCMV)] infections tolerance
is the result of suppressive PD-L1 (CD274) signals that engage
T cell expressed PD-1 (CD279) receptors, limiting effector T cell
clearance and causing T cell anergy (Mueller et al., 2010; Wei et al.,
2013; Penaloza-MacMaster et al., 2014). Although the role of EC-
derived PD-L1 has not been studied during AV infections, PD-L1
inhibits T cell targeting, lysis and immunopathology but may also
play a unique role in tolerance that is linked to EC permeability
(Rodig et al., 2003; Brooks et al., 2008; Tewalt et al., 2012b).
A pointed demonstration of PD-L1/PD-1 responses in hemor-
rhagic and edematous diseases is provided by findings that LCMV
infection of PD-1 knockout mice resulted in a dramatic increase
in pulmonary edema as well as increased edema in brain, liver
and kidney (Frebel et al., 2012). Consistent with this, pulmonary
edema was also observed in wt LCMV infected mice treated with
a blocking antibody to PD-L1 (Frebel et al., 2012). PD-1 KOs had
increased plasma thrombin-antithrombin III (ATIII) levels and
a 90% reduction in platelet levels, further suggesting a role for
dysregulated PD-L1/PD-1 responses in thrombocytopenia during
viral infections.
Less is known about EC mediated tolerance and its potential
role in viral hemorrhagic and edematous disease (Rodig et al.,
2003; Tewalt et al., 2012a,b). Microvascular and lymphatic ECs
(MECs and LECs) regulate vessel integrity and fluid clearance
functions of lymphatics (Aird, 2008; Schraufnagel, 2010). How-
ever, they also serve as non-professional antigen presenting cells
that line lymphoid tissues and capillaries and are reportedly
essential for establishing tolerance to antigens present within
the endothelium (Aird, 2008; Schraufnagel, 2010; Tewalt et al.,
2012a,b). EC induced tolerance restricts T cell targeting of anti-
gens within the endothelium and at one level controls immune
mediated vascular leakage (Tewalt et al., 2012a,b). This ploy
appears to be engaged by several viruses that induce persistence,
but with the wrong viral protein repertoire, attempted tolerance
may instead increase the duration of EC infection and uncouple
normally balanced hemostatic functions.
The role of the endothelium in tolerance and vascular
permeability is simplified in hantavirus (HV) infections where
HVs nearly exclusively replicate in ECs of humans and hosts
(Zaki et al., 1995; Mackow et al., 2013; Vaheri et al., 2013).
HVs persistently infect their small mammal hosts without
causing disease, but like AV and EBOV cause thrombocytopenia
and vascular leakage 1–3 weeks after infection of humans
(Gavrilovskaya et al., 1990; Zaki et al., 1995). Although HVs
infect ECs throughout the body they cause overt disease in
expansive EC capillary beds of the lungs and kidneys resulting in
hantavirus pulmonary syndrome (HPS; Duchin et al., 1994; Zaki
et al., 1995; Bustamante et al., 1997; Koster and Mackow, 2012)
and hemorrhagic fever with renal syndrome (HFRS; Cosgriff and
Lewis, 1991; Lahdevirta, 1982).
A compelling case is emerging for HVs to induce EC directed
T cell regulation and tolerizing responses that contribute to
disease. MECs and LECs express inhibitory PD-L1 receptors on
their surfaces that suppress CD4+ and CD8+ T-cell responses
and induce tolerance (Rodig et al., 2003; Tewalt et al., 2012a,b).
PD-L1/PD-1 responses form a fundamental immune regulatory
paradigm that controls CD4+ T cell exhaustion and is resolved
by a PD-L1 blockade (Francisco et al., 2009, 2010; Penaloza-
MacMaster et al., 2014). During acute human HV infections that
cause HPS, ECs in the lung are uniformly and singularly infected
resulting in acute pulmonary edema with exudates accumulating
at up to 1 l per hour (Zaki et al., 1995; Bustamante et al., 1997).
In HPS, immunoblasts (>10%) are a feature of infection and
present at high levels in lymphoid organs and concentrated in
the lung at autopsy (Zaki et al., 1995). Its unclear whether HV
infection of pulmonary ECs tolerizes or arrests immunoblasts
(Zaki et al., 1995) or observed T cell responses (Ennis et al., 1997;
Kilpatrick et al., 2004), but even at autopsy there is little evidence
of endothelial cytopathic effect during HPS and no hemorrhagic
disease indicative of a capillary breech (Zaki et al., 1995). While
regulatory CD4 or CD8 T cell responses were not observed during
HFRS infections, activated CD4 and CD8 T cells were observed
during human Puumala virus (HV) infections (Lindgren et al.,
2011). However, Puumala virus causes more of an early acute
infection and there is no indication of the T cell responses relative
to disease (Terajima et al., 2007; Lindgren et al., 2011). Even in
this setting CD4 and CD8 T cells were found to express inhibitory
receptors (PD-1, CTLA-4, or both) that may balance effector
functions with tolerance (Lindgren et al., 2011). Consistent with
HPS responses in patients, both hypoxia and interferons induce
the expression of PD-L1 (Schreiner et al., 2004; Muhlbauer et al.,
2006; Noman et al., 2014). The Seoul HV reportedly increases
PD-L1 expression levels during in vitro infection of ECs (Li and
Klein, 2012) and our recent findings indicate that pathogenic HV
infection (ANDV, HPS), but not infection by non-pathogenic
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TULV, upregulates PD-L1 levels on the surface of ECs. These
findings may link EC expressed PD-L1 to the increased duration
of viral infections of the endothelium that may contribute to EC
dysfunction (Mueller et al., 2010). These findings also suggest a
mechanism for HV infected ECs to inhibit T cell responses via
PD-L1/PD-1 regulation.
Hantavirus induced T cell exhaustion could also explain why T
cell depletion therapy was found to have no effect on the timing,
onset or severity of lethal HPS disease in ANDV infected Syrian
hamsters, and why steroid immunosuppression actually permits
SNV directed HPS in this model (Hammerbeck and Hooper,
2011; Brocato et al., 2014). These finding suggest that T cell
responses may already be suppressed by ANDV infection and that
immune mediated disease isn’t a likely cause of vascular perme-
ability in HPS. In a lethal non-human primate HPS model, T cell
responses and inflammatory cytokines were absent 12 dpi even
though radiographic pulmonary edema and cardiac enlargement
were observed 6–9 and 12 dpi, respectively, and prior to T cell
and cytokine responses (first noted 18–21 dpi; Safronetz et al.,
2014). Although it was not determined whether T cells were PD-1
or CTLA-4 positive, HVs fail to establish persistence in humans
and tolerizing responses may alter the timing, vigor and targeting
of T cell responses that normally clear infection (Terajima et al.,
2007; Mueller et al., 2010). The extended HV infection of MECs
and LECs may also dysregulate functions of the endothelium
that control: platelet activation and recruitment (Raymond et al.,
2005; Sohn et al., 2005; Gavrilovskaya et al., 2010), EC responses
to a plethora of potential permeabilizing factors (Nagy et al.,
2008; Dvorak, 2010; Gorbunova et al., 2010; Taylor et al., 2013),
fluid clearance from tissues by lymphatic vessels and capillary
tone (Luscher and Barton, 1997; Yang et al., 2004; Aird, 2008;
Gavrilovskaya et al., 2012; Lin et al., 2013). Given the delicate bal-
ance of hemostatic factors regulated by ECs, it is unclear whether
targeting platelets, ECs or β3 integrin receptors, or effecting a PD-
L1 blockade/Il-2 stimulation to restore viral clearance, would be
therapeutic or deleterious to the endothelium and lethal capillary
leakage (Kamphorst and Ahmed, 2013; West et al., 2013).
ENDOTHELIAL CELL FUNCTIONS
Several excellent reviews detail the wealth of systems at play in
the endothelium and their dynamic management of capillary
functions (Luscher and Barton, 1997; Willoughby and Loscalzo,
2002; Orfanos et al., 2004; Nagy et al., 2008; Pober et al., 2009).
Under normal conditions, the endothelium constitutively directs
the inactivation of platelets, clotting and complement cascades
and prevents the adherence of immune cells and platelets to ECs
(Figure 1). However, ECs also dynamically respond to conditions
in order to activate platelets, secrete chemokines, recruit and
FIGURE 1 | Endothelial cell functions that maintain hemostasis.
Endothelial cells are primary anticoagulants that prevent platelet and immune
cell adherence and restrict the activation of clotting cascades (Hoffman and
Monroe, 2001; Feletou, 2011). ECs display tissue plasminogen activator (t-PA)
but constitutively secrete plasminogen activator inhibitor type I (PAI-I). ECs
constitutively express tissue factor pathway inhibitor (TFPI) on their surfaces
that counteracts tissue factor activated coagulation. ECs regulate thrombin
(Throm) activation by presenting anti-thrombin-III (AT-III) and thrombomodulin
(TM) on their surfaces which respectively bind and inactivate thrombin or
direct thrombin activation of protein C (APC). ECs express eNOS which
directs the production of nitric oxide and secrete prostaglandin I2 (PGI2,
prostacyclin) that both inhibit platelet activation and aggregation and are
potent vasodilators that increase blood flow (Pober and Sessa, 2007).
However, ECs also express von Willebrand factor within storage granules and
secrete the platelet activating factor that activate platelets. ECs restrict
responses of immune cells by expressing the T-cell activation inhibitor PD-LI
on their surfaces and secreting NO and by preventing the expression of
immune recruiting receptors like intercellular cell adhesion molecule-1 (ICAM)
or vascular cell adhesion molecule (VCAM). ECs constitutively express αvβ3
integrins on their surface that are required for EC migration and regulate
vascular endothelial growth factor receptor 2 (VEGFR2) responses to the
VEGF, a potent edemagenic factor, first discovered as a permeability factor.
Hypoxia, angiogenesis and extravasation of immune cells requires
dissociation of adherens junctions in order to restore tissue oxygenation and
effect EC migration and vascular repair. These processes and responses to
histamine, platelet activating factor VEGF, bradykinin along with shear stress
and dilatory stretching of the endothelium can increase vascular permeability
and are regulated by circulating soluble receptors or degradative systems
which normally limit VEGF and bradykinin effects in order to maintain
hemostasis. Viral infection of the endothelium has the potential to alter the
delicate balance of these interrelated systems and signals to direct
fibrinoloysis and disseminated intravascular coagulation, activate permeability
pathways, alter platelet responses, and control immune cell recognition of the
endothelium. Each virus mentioned appears to perturb these functions in
unique ways that are enhanced by prolonged infection of ECs, platelet
dysfunction and failed immune clearance. A more complete analysis of
hemostatic control mediated by ECs and extensive figures on the subject are
present in several excellent reviews (Luscher and Barton, 1997; Hoffman and
Monroe, 2001; Aird, 2004, 2008; Pober and Sessa, 2007; Martina et al., 2009;
Feletou, 2011).
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extravasate immune cells and control vessel dilation and repair
(Aird, 2008). This is accomplished through a combination of EC
specific proliferative responses, receptors and permeability factors
that both act on the endothelium or are secreted or expressed
by ECs.
EC DIRECTED HEMOSTASIS: PLATELETS, COAGULATION,
VESSEL TONE, AND PERMEABILITY
A detailed understanding of hemostasis is beyond the scope and
focus of this paper but several excellent reviews address these
interrelated responses that are controlled by ECs (Hoffman and
Monroe, 2001; Aird, 2008; Pober et al., 2009; Dvorak, 2010;
Feletou, 2011). Hemostasis is maintained by EC interactions with
platelets and regulation of fibrin formation. The endothelium is
normally quiescent and does not recruit platelets or immune cells
or direct fibrinolysis or coagulation. ECs are dedicated to remain-
ing inert and preserving this balance, however disrupting the
endothelium exposes subendothelial matrix that directs platelet
activation and adherence through integrin receptors. ECs store
and release von Willebrand factor (vWF) which stabilizes Factor
VIII and furthers platelet receptor interactions (Hoffman and
Monroe, 2001). ECs also synthesize and release platelet activating
factor (PAF) that further promotes platelet adherence to ECs.
Tissue factor (TF) is a cell associated coagulation activator that
is present in the extracellular matrix and initiates coagulation
cascades following exposure of blood to the tissue. TF initiates a
cascade that results in the generation of thrombin and the cleavage
of fibrinogen to fibrin which aggregates platelets.
Several EC directed mechanisms inhibit coagulation in order
to prevent platelet adhesion and aggregation (Hoffman and Mon-
roe, 2001; Pober and Sessa, 2007; Pober et al., 2009; Feletou,
2011). ECs express TF pathway inhibitor (TFPI) on their surfaces
which prevents TF directed coagulation and present ATIII on
their surfaces which inactivates thrombin. ECs highly express
thrombomodulin (TM) on their surfaces which binds thrombin
and converts it to an anticoagulant by binding and activating
protein C (Figure 1). Activated protein C binds protein S and
inactivates factor Va and VIIIa. ECs normally mask signals that
recruit platelets and express prostaglandin I2 (prostacyclin) and
nitric oxide (NO) which both inhibit platelet adhesion and direct
vasodilation that increases blood flow (Hoffman and Monroe,
2001; Pober and Sessa, 2007; Pober et al., 2009; Feletou, 2011).
Fibrinolysis is also EC regulated since ECs constitutively syn-
thesize tissue-type plasminogen activator (t-PA) and induce t-
PA in response to shear stress, thrombin and bradykinin (Fele-
tou, 2011). However, this activity is controlled by plasmino-
gen activator inhibitor type I (PAI-I) that is also constitutively
secreted by ECs. Collectively these EC regulated responses control
coagulation, dilation, fibrinolysis and thrombosis that may be
altered during viral infection of the endothelium resulting in
aberrant coagulation and hemostatic responses that contribute to
disseminated intravascular coagulation (DIC), hemorrhage and
edema (Figure 1).
Endothelial barrier functions can be altered by many of the
components above that control hemostasis by directing changes
in inter-EC junctions and result in edema or hemorrhage. Medi-
ators of EC permeability include histamine, serotonin thrombin,
bradykinin, PAF, cytokines and several growth factors including
EC specific vascular endothelial growth factor (VEGF) that direct
angiogenesis and repair (Dvorak, 2006, 2010; Feletou, 2011).
Hypoxic conditions within tissues direct vascular permeability
and vessel repair which by necessity loosens EC connections to
permit EC migration. Edema results from an excess of fluid in
the tissues relative to the ability of lymphatic vessels to remove
interstitial fluid (Figure 1). Not surprisingly, these overlapping
functions and feedback mechanisms, which are in place to pre-
vent lethal vascular leakage, are altered by viral infection of ECs
and fundamental to severe endothelial dysfunction syndromes
directed by viruses.
VIRAL REGULATION OF ENDOTHELIAL SIGNALING
PATHWAYS
Successful viral infections are accompanied by the regulation
of Type I interferon (in ECs IFNβ) responses that are present
to innately control their replication. AVs, EBOVs, HVs, and
dengue virus (DV) all regulate signaling pathways that induce
IFN induction or cellular responses to IFN receptor activation
(Alff et al., 2006; Rodriguez-Madoz et al., 2010; Luthra et al.,
2013; Cimica et al., 2014). But late in infection IFN responses
are induced by all these viruses. However, both the induction of
IFN and cellular responses to exogenous IFN are unique in ECs.
In contrast to immune cells which apoptotically respond to IFN,
ECs treated with type I IFN proliferate (Gomez and Reich, 2003),
protecting and enhancing barrier functions of the endothelium
following viral infections. These findings suggest that early viral
inhibition of IFN secretion and later IFN induction may positively
or negatively impact vascular permeability of the virally infected
endothelium (Schreiner et al., 2004). The protective role of IFN
on the endothelium questions the use of IFN receptor knockouts
to study the pathogenesis of virally induced vascular hemorrhagic
and edematous disease (Williams et al., 2009; Zust et al., 2014).
HV proteins inhibit IFN induction by binding TRAF3, and
blocking TBK1 directed responses (Alff et al., 2008; Cimica et al.,
2014; Matthys et al., 2014). Similar pathway targeting occurs in
AV, EBOV, and DV infections (Rodriguez-Madoz et al., 2010;
Pythoud et al., 2012; Rodrigo et al., 2012; Luthra et al., 2013).
TBK1 and TRAF3 are tied to NF-κB and VEGF/hypoxia to
mTOR signaling pathways that control EC survival, growth factor,
cytokine, hypoxia, and hemostatic responses (Venkatesha et al.,
2004; Sohn et al., 2005; Madge and May, 2010; Hacker et al.,
2011; Laplante and Sabatini, 2012). Curiously, TBK1, which is
normally expressed at catalytic levels in most cells (Hacker et al.,
2011; Tu et al., 2013), is expressed at high levels in primary
human ECs. Although the significance of this remains to be
determined, these findings point to the novel wiring and regu-
lation of signaling pathways within ECs and as a result, unique
signaling pathway regulation following viral infection of the
endothelium.
Activating endothelial NF-κB plays a critical role in toler-
ance, inflammation and vascular barrier dysfunction (Sehnert
et al., 2013). In ECs NF-κB induces TF, endothelin-1 (ET-1),
COX-2, eNOS, prostaglandins (PGI2/PGE2), PD-L1, chemokines
(CXCL12, IL6,8), and inhibits TM (Friedl et al., 2002; Willoughby
and Loscalzo, 2002; Sohn et al., 2005; Oganesyan et al., 2006;
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He et al., 2007; Pober and Sessa, 2007; Pober et al., 2009;
Charoenthongtrakul et al., 2013; Lin et al., 2013). These context
dependent responses control capillary tone (COX2, NO, ET-1,
PGI2), permeability (TF/TM), immune cell recruitment and acti-
vation (chemokines, PD-L1), and platelet activation/inhibition
(PGE2/PGI2/TM) that impact vascular hemostasis (Figure 1).
ECs control fibrinolysis by balancing the expression of t-PA, PAI,
ATIII, TM, and PAF that are dynamically regulated (Hoffman and
Monroe, 2001; Willoughby and Loscalzo, 2002; Orfanos et al.,
2004; Pober and Sessa, 2007; Feletou, 2011). Several of these
components are associated with acute respiratory distress syn-
dromes and are impacted by EC generated angiotensins, kinins,
growth factors and integrins that control angiogenesis, platelets,
capillary tone, and permeability (Pober and Sessa, 2007; Pober
et al., 2009; Feletou, 2011; Taylor et al., 2013; Vaheri et al., 2013).
Given the delicate balance of EC regulated hemostatic responses,
an extended viral infection of endothelium alone has the potential
to cause thrombocytopenia, capillary dilation/contraction and
vascular permeability that are the crux of viral hemorrhagic and
edematous diseases.
VIRAL REGULATION OF PLATELETS AND PERMEABILITY
As mentioned above many factors are reported to induce per-
meability by acting on EC-specific or EC-related targets. HV
infection of ECs alters platelet, cytokine and permeability factor
responses (Mackow and Gavrilovskaya, 2009) and suggests mech-
anisms of EC dysregulation common to viruses that cause vascu-
lar leakage (Cosgriff et al., 1991; Zaki et al., 1995; Willoughby and
Loscalzo, 2002; Olsson et al., 2003). Unique vascular EC adhesion
molecules (i.e., VE-cadherin) form adherence junctions between
adjacent ECs and form the primary fluid barrier of capillaries.
ECs also uniquely express VEGF receptors (VEGFRs) that are
activated by the binding of VEGF, a factor first described as a
potent edemagenic vascular permeability factor, and controlled
by a number of receptors and signaling pathways (Dvorak, 2006;
Olsson et al., 2006). ECs also uniquely respond to angiopoi-
etins 1/2 which either stabilize or enhance vascular permeability.
VEGF directs localized angiogenic repair through EC dissociation
and proliferation, is induced by hypoxia, contributes to high
altitude induced pulmonary edema and causes chronic vascular
hyperpermeability (Berger et al., 2005; Nagy et al., 2007). VEGF
also induces EC expression of TF which triggers clotting and
fibrinolysis that impact both platelet activation and permeabil-
ity (Wood et al., 2014) and hypoxia induced PD-L1 may con-
tribute to T cell regulation during viral infections (Noman et al.,
2014).
Tissue factor was shown to be upregulated following EBOV
infections of macaques suggesting that altered coagulation
responses may contribute to DIC observed during EBOV infec-
tion (Geisbert et al., 2003a,b). EBOV infected ECs showed no
sign of significant cytolytic effects and viral replication was not
consistently seen in ECs till a day after DIC was noted (Geisbert
et al., 2003b,c). Interestingly, TF activation is associated with EC
permeability only when Factor VIII is also depleted, suggesting
that additional EC regulated coagulation responses are likely
to be altered in order to direct capillary leakage (Friedl et al.,
2002; Frueh et al., 2013). Using a TF inhibitor resulted in a
33% survival rate of infected macaques and a 3 day increase
in the survival time of remaining animals (Geisbert et al.,
2003a). These findings suggest the potential for anti-coagulation
therapy in targeting and restoring hemostasis during EBOV
infections.
Pathogenic HVs bind and dysregulate αvβ3 integrins on ECs
that normally restrict VEGF directed permeability by binding
VEGFR2 (Gavrilovskaya et al., 1999; Borges et al., 2000; Ray-
mond et al., 2005; Coller and Shattil, 2008; Figure 1). In vitro,
HVs coat the surface of infected ECs >3 days post-infection
and render infected ECs hyperresponsive to VEGF and hypoxia
directed permeability (Gavrilovskaya et al., 2008, 2013). HVs
present on the EC surface bind to quiescent platelets via αIIbβ3
integrins and 3 days post-infection recruit platelets to EC sur-
faces (Gavrilovskaya et al., 2010). These findings are consistent
with HV inhibiting αIIbβ3 platelet activating functions and a
potential mechanism of thrombocytopenia that results in the
quiescent recruitment of platelets to the surface of the HV
infected endothelium. Covering the EC with a coat of quies-
cent platelets may also serve as a mechanism for HVs to evade
immunosurveillance and suggests that HVs may induce platelet
inhibitors PGI2/prostacyclin/TM and restrict platelet αIIbβ3 inte-
grin responses during infection of the endothelium.
ENDOTHELIAL CELL TARGETING AND IMMUNE MEDIATED
DENGUE VIRUS PERMEABILITY
Vascular leakage caused by DV infections presents a unique
immune enhanced paradigm that requires preexisting anti-DV
antibodies (Halstead, 2003). DVs are transmitted to man from
infected mosquitoes and infect immune, dendritic and ECs (Hal-
stead, 1988; Jessie et al., 2004; Balsitis et al., 2009; Dalrymple and
Mackow, 2012b). Roles for tolerance in hosts are not rationalized
in this setting and initial DV infections are typical acute RNA
virus infections with little delay in onset, and flu-like symptoms
predominant in DF: high fever, IFN and cytokine responses
(Halstead, 2008). In contrast, DHF or DSS (systemic edema)
result from an enhanced immune response following infection by
a second DV serotype and occur over a 1–2 week period similar to
AV, EBOV, and HV (Halstead, 1988). Vascular leakage follows the
cessation of fever and virema and coincides with the late onset of
thrombocytopenia which remains a central finding in DHF and
DSS (Halstead, 2002; Noisakran et al., 2009) and mimics other
thrombocytopenia associated diseases (Harker and Slichter, 1972;
Nguyen and Carcillo, 2006).
The same cytokine responses are reported during initial and
secondary DV infections, strongly suggesting that DV induced
cytokines alone are insufficient to cause DHF or DSS (Halstead,
2002, 2008). DV infected ECs have been documented in several
organs at autopsy (Jessie et al., 2004; Balsitis et al., 2009), and
roles for ECs in DHF and DSS are without question, but poorly
understood due to the invasive nature of analysis required and
the relatively low mortality associated with disease. DV infec-
tion of primary human ECs is rapidly productive and elicited a
constellation of chemokine responses found in patients that may
foster an immune enhancing disease process and EC targeting
(Halstead, 2008; Dalrymple and Mackow, 2012a,b, 2014). Initial
DV infections appear to prime immune responses to crossreactive
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non-structural DV antigens during a second infection and thus
effector T cell recruitment and immune targeting of platelets and
ECs are potential causes of vascular leakage (Lei et al., 2001;
Cardier et al., 2006; Chen et al., 2009). Variation in the magnitude
and specificity of initial infections may impact individual DHF
or DSS responses during secondary infections (Zellweger et al.,
2010). The absence of animal models of DV disease and findings
that DHS and DSS occur in ∼1% of human DV infections (Hal-
stead, 2008) further complicate the development of viable disease
models (Balsitis and Harris, 2010; Tan et al., 2010; Zellweger et al.,
2010) and the causes of DV induced hemorrhagic and edematous
disease.
CONCLUSIONS AND DIRECTIONS
Virally induced changes in EC responses remain poorly under-
stood but fundamental to capillary leakage, edema and hem-
orrhagic diseases. The likely ability of AV, EBOV, and HVs to
persistently infect their hosts without disease and tolerize host
immune responses provides a notable divergence between asymp-
tomatic and pathogenic infections of the endothelium. In humans
these viruses fail to establish persistence or tolerance and cause
lethal hemorrhagic or edematous diseases that have in common
the ability to infect the endothelium and, after long onset, cause
thrombocytopenia and capillary leakage. The long prodromal
period is consistent with attempted tolerance and the regulation
of early immune responses that permit an extended period of EC
infection. The balance of EC functions that these viruses maintain
in their hosts are unsuitable for preserving human hemostasis
with lethal vascular consequences. EC directed immune regu-
lation is suggested during HV infection, while AV and EBOV
infect both ECs and immune cells that may jointly defeat, tolerize
or reduce early T cell clearance responses. Thrombocytopenia is
caused by platelet consumption, aggregation, sequestration, or
quiescence and is likely to be uniquely induced by each virus
depending on the EC effector pathways and cellular receptors that
are impacted. The feedback regulation and overlapping functions
that maintain vascular stasis suggest that viruses alter several EC
systems in order to cause hemorrhage and edema.
Currently we have little understanding of the changes that
occur in virally infected ECs that might alter EC barrier functions.
However, the myriad of hemostatic systems that may be altered
by viral infection of the endothelium demonstrates the essential
nature of defining virally induced changes in EC responses that
direct hemorrhagic and edematous disease. During viral infection
of ECs there is a desperate need to resolve responses that direct
platelet and capillary dysfunction and reveal unique viral interac-
tions with human EC proteins and signaling pathways. Without
this information it is hard to realistically consider therapeutic
targeting the intricate network of EC responses required to restore
homeostasis following infection by hemorrhagic and edematous
viruses.
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